Scarica l'app Stockscreener
0.9568
4.97%
0.0453
Dopo l'orario di chiusura:
1.00
0.0432
+4.52%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché PYXS Giù?
Forum
Previsione
Pyxis Oncology Inc Borsa (PYXS) Ultime notizie
Pyxis Oncology stock plunges to 52-week low of $0.86 - Investing.com India
Layoff Tracker: Relay Will Cut 70 Employees, Affecting Research Budget by 75% - BioSpace
Pyxis Oncology to Participate in the Stifel 2025 Virtual Targeted Oncology Forum - The Manila Times
Pyxis Oncology stock hits 52-week low at $0.98 amid downturn - Investing.com Canada
Is it possible to buy Pyxis Oncology Inc(PYXS) shares at a good price now? - US Post News
Pyxis Oncology to Present New Preclinical Data Supporting Development of First-In-Concept ADC Targeting EDB+FN in Tumor Microenvironment at AACR 2025 - The Manila Times
Pyxis Oncology to Present Preclinical Data for Micvo Cancer Drug Candidate - MarketScreener
Breakthrough Cancer Drug Achieves Major Milestones: FDA Fast-Tracks Pyxis's Revolutionary Tumor Treatment - Stock Titan
Pyxis Oncology Highlights Strategic Focus on Lead Candidate - TipRanks
Pyxis Oncology, Inc. (NASDAQ:PYXS) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World
Analysts Set Expectations for Pyxis Oncology Q1 Earnings - Defense World
HC Wainwright Expects Stronger Earnings for Pyxis Oncology - Defense World
Royal Bank of Canada Reiterates Outperform Rating for Pyxis Oncology (NASDAQ:PYXS) - Defense World
Optimistic Buy Rating for Pyxis Oncology Amid Strategic Focus and Promising Drug Developments - TipRanks
William Blair Weighs in on Pyxis Oncology FY2027 Earnings - Defense World
HC Wainwright Reiterates Buy Rating for Pyxis Oncology (NASDAQ:PYXS) - Defense World
Pyxis Oncology Inc reports results for the quarter ended December 31Earnings Summary - TradingView
RBC Capital Remains a Buy on Pyxis Oncology (PYXS) - The Globe and Mail
Pyxis Oncology Advances Cancer Therapeutics with MICVO - TipRanks
Jefferies cuts Pyxis Oncology target to $6, maintains Buy By Investing.com - Investing.com Australia
Jefferies cuts Pyxis Oncology target to $6, maintains Buy - Investing.com India
Pyxis Oncology Announces CMO Resignation and New Trials - TipRanks
Pyxis Oncology, Inc. SEC 10-K Report - TradingView
Pyxis Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - The Manila Times
Pyxis Oncology Reports Promising Phase 1 Data for MICVO in Head and Neck Cancer, Receives FDA Fast Track Designation - Nasdaq
Empress Therapeutics confirms layoffs; Nanobiotix amends J&J deal terms - Endpoints News
Pyxis Oncology Inc expected to post a loss of 33 cents a shareEarnings Preview - TradingView
Pyxis Oncology (PYXS) to Release Earnings on Thursday - Defense World
Closing Figures Unveiled: Pyxis Oncology Inc (PYXS) Drop -2.80, Closes at 1.04 - The Dwinnex
Pyxis Oncology to Participate at the Leerink Partners Global Healthcare Conference - The Manila Times
Can Pyxis Oncology's CEO Reveal New Cancer Treatment Progress at Upcoming Leerink Conference? - StockTitan
FDA Grants PYX-201 Fast Track Status in HNSCC - Targeted Oncology
Pyxis Oncology Granted FDA Fast Track Designation for - GlobeNewswire
Pyxis Oncology's US$8.9m Market Cap Fall Books Insider Losses - Simply Wall St
Pyxis Oncology rises on FDA fast track tag for lead asset - MSN
Pyxis Oncology, Inc. Grants Fast Track Designation for PYX-201 Monotherapy in Patients with Recurrent or Metastatic Head and Neck Cancer - Marketscreener.com
FDA fast tracks Pyxis Oncology's head and neck cancer drug By Investing.com - Investing.com Canada
Pyxis Oncology Gets Fast Track Designation For PYX-201 In Head And Neck Cancer - Nasdaq
PYXSPyxis Oncology, Inc. Latest Stock News & Market Updates - StockTitan
FDA fast tracks Pyxis Oncology’s head and neck cancer drug - Investing.com India
Pyxis Oncology stock up on FDA fast track tag (PYXS:NASDAQ) - Seeking Alpha
Pyxis Oncology Granted FDA Fast Track Designation for PYX-201 Monotherapy in Patients with Recurrent or Metastatic Head and Neck Cancer - The Manila Times
Pyxis Oncology Announces Fast Track Designation from FDA for PYX-201 in Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma - Nasdaq
Could This FDA Fast Track for Pyxis Oncology's Novel Cancer Drug Accelerate Treatment Options? - StockTitan
Pyxis Oncology, Inc. (NASDAQ:PYXS) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World
Pyxis Oncology (NASDAQ:PYXS) Shares Down 4.7% – Here’s What Happened - Defense World
Pyxis Oncology stock hits 52-week low at $1.23 amid downturn By Investing.com - Investing.com South Africa
Pyxis Oncology stock hits 52-week low at $1.23 amid downturn - Investing.com Canada
Will Pyxis Oncology (NASDAQ:PYXS) Spend Its Cash Wisely? - Yahoo Finance
Pyxis Oncology Inc [PYXS] Investment Appeal on the Rise - Knox Daily
Nothing is Better Than Pyxis Oncology Inc (PYXS) stock at the moment - SETE News
Pyxis Oncology Inc [PYXS] Investment Guide: What You Need to Know - Knox Daily
Financial Health Report: Pyxis Oncology Inc (PYXS)’s Ratios Tell a Tale - The Dwinnex
Pyxis Oncology, Inc. (NASDAQ:PYXS) Given Average Rating of “Moderate Buy” by Analysts - Armenian Reporter
0.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):